Zhongtai Securities released a research report on April 21 stating that it gave Jichuan Pharmaceutical (600566.SH) a purchase rating. The main reasons for the rating include: 1) Q1 performance surpassed expectations, and the return home achieved 25% growth; 2) cost-side optimization led to a significant increase in net interest rates. (Mainichi Keizai Shimbun)
中泰证券4月21日发布研报称，给予济川药业（600566.SH）买入评级。评级理由主要包括：1）Q1业绩大超预期，归母实现25%增长；2）费用端优化带来净利率明显提升。（每日经济新闻）
Zhongtai Securities released a research report on April 21 stating that it gave Jichuan Pharmaceutical (600566.SH) a purchase rating. The main reasons for the rating include: 1) Q1 performance surpassed expectations, and the return home achieved 25% growt
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.